Recently, it was reported that a high‐frequency of KMT2C/D mutations could be a biomarker for PARP inhibitor therapy response in non‐small‐cell lung cancer (NSCLC) and other cancer types.31 This evidence concerns the gene PARP1 and non-small cell lung carcinoma.